The Food and Drug Administration granted Breakthrough Therapy Designation to Proteostasis Therapeutics Inc.'s (Nasdaq: PTI) cystic fibrosis transmembrane conductance regulator amplifier PTI-428. Shares of the biopharmaceutical surged $2.24 to close at $6.38.
Breakthrough Designation granted to Proteostasis Therapeutics
March 13, 2018 at 17:14 PM EDT
